• 1
    Stedman's Medical Dictionary, 27th edn. Lippincott, Williams, and Wilkins, Philadelphia, PA, 2000.
  • 2
    Solomon DA, Leon AC, Mueller TI et al. Tachyphylaxis in unipolar major depressive disorder. J. Clin. Psychiatry 2005; 66: 283290.
  • 3
    Rothschild A. The Rothschild scale for antidepressant tachyphylaxis. Poster presented at: 159th Annual Meeting of the American Psychiatric Association; May 20–25, 2006; Toronto, Canada.
  • 4
    Rothschild A. The Rothschild scale for antidepressant tachyphylaxis: reliability and validity. Compr. Psychiatry 2008; 49: 508513.
  • 5
    Katz G. Tachyphylaxis /tolerance to the antidepressive medications: a review. Isr. J. Psychiatry 2010 (in press).
  • 6
    Byrne S, Rothschild A. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J. Clin. Psychiatry 1998; 59: 279288.
  • 7
    Posternak MA, Zimmerman M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. J. Clin. Psychiatry 2005; 66: 705707.
  • 8
    American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision. American Psychiatric Press, Inc, Washington, DC, 2000.
  • 9
    Sansone RA, Sansone LA. Dysthymic disorder: forlorn and overlooked? Psychiatry (Edgmont) 2009; 6: 4651.
  • 10
    Weissman MM, Leaf PJ, Bruce ML, Florio L. The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment. Am. J. Psychiatry 1988; 145: 815819.
  • 11
    Wittchen HU, Knäuper B, Kessler RC. Lifetime risk of depression. Br. J. Psychiatry Suppl. 1994; 26: 1622.
  • 12
    Ghaemi SN. Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disord. 2008; 10: 957968.
  • 13
    Cuijpers P, van Straten A, Schuurmans J, van Oppen P, Hollon SD, Andersson G. Psychotherapy for chronic major depression and dysthymia: a meta-analysis. Clin. Psychol. Rev. 2010; 30: 5162.
  • 14
    Cornelisse LN, Van der Harst JE, Lodder JC et al. Reduced 5-HT1A- and GABAB receptor function in dorsal raphé neurons upon chronic fluoxetine treatment of socially stressed rats. J. Neurophysiol. 2007; 98: 196204.
  • 15
    Rothschild AJ, Dunlop BW, Dunner DL et al. Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine ER for Two Years (PREVENT) Study. Psychopharmacol. Bull. 2009; 42: 520.
  • 16
    Amsterdam J, Williams D, Michelson D et al. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology 2009; 59: 227233.
  • 17
    Fournier JC, DeRubeis RJ, Hollon SD et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 4753.
  • 18
    de Lima MS, Hotoph M, Wessely S. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychol. Med. 1999; 6: 12731289.
  • 19
    Lima MS, Moncrieff J. Drugs versus placebo for dysthymia. Cochrane Database Syst. Rev. 2000; (4): CD001130.
  • 20
    Dunner DL. Acute and maintenance treatment of chronic depression. J. Clin. Psychiatry 2001; 62 (Suppl. 6): 1016.
  • 21
    Zimmerman M, Thongy T. How often do SSRIs and other new-generation antidepressants lose their effect during continuation treatment? Evidence suggesting the rate of true tachyphylaxis during continuation treatment is low. J. Clin. Psychiatry 2007; 68: 12711276.
  • 22
    Thase MA. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr. 2006; 11: 1221.
  • 23
    Byrne S, Rothschild AJ. Psychiatrists' responses to failure of maintenance therapy with antidepressants. Psychiatr Serv. 1997; 48: 835837.
  • 24
    Fichtner CG, Jobe TH, Braun BG. Possible therapeutic window for serotonin reuptake inhibitors. J. Clin. Psychiatry 1994; 55: 3638.
  • 25
    Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a ‘therapeutic window’? J. Clin. Psychiatry 1992; 53: 272277.
  • 26
    Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J. Affect. Disord. 2009; 116: 411.
  • 27
    Leykin Y, Amsterdam JD, DeRubeis RJ, Gallop R, Shelton RC, Hollon SD. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J. Consult. Clin. Psychol. 2007; 75: 267276.
  • 28
    Amsterdam J, Shultz J. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode? J. Affect. Disord. 2009; 115: 234240.